Long-acting bronchodilators are recommended as maintenance therapy for chronic
obstructive pulmonary disease (COPD)(1). Dual therapy using long-acting muscarinic …

The development of inhalers containing both a longacting muscarinic antagonist (LAMA)
and a long-acting beta agonist (LABA) has increased the treatment options in chronic …

Dual bronchodilation therapy is the cornerstone for the treatment of chronic obstructive
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …

Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …

Introduction Long-acting muscarinic receptor antagonist (LAMA)/β2-agonist (LABA)
combinations represent a significant improvement in the treatment of chronic obstructive …

Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary
disease (COPD). Despite the number and types of treatments available, the control of …

Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

Current guidelines recommend treatment with one or more bronchodilators for chronic
obstructive pulmonary disease (COPD) patients. Combination therapy with long-acting …

Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory
symptoms, such as breathlessness and chronic productive cough, limited exercise …